In the present edition of the OC Journal, focusing on genitourinary cancer, we selected two papers presented at the ASCO congress, which took place last June, in an exceptionally virtual format.
LACOG 0415 was the first randomized study to evaluate different therapeutic strategies with the new androgen synthesis inhibitor agents (abiraterone/prednisone [AAP] and apalutamide [APA]) in combination, with or without TPA, in hormone metastatic prostate cancer. -sensitive. Mariane Sousa Fontes Dias, clinical oncologist specializing in genitourinary tumors at Oncoclínica Botafogo (Rio de Janeiro), a clinic of the Oncoclínicas Group, highlights that the AAP+ADT and AAP+APA arms reached the primary outcome (75.6% and 79.5 %). On the other hand, the arm with APA in monotherapy (60%) did not obtain the predetermined cut-off value.
The JAVELIN Bladder 100 study evaluated the role of maintenance immunotherapy with avelumab (anti-PDL-1) in patients previously treated with platinum-based chemotherapy (cisplatin or carboplatin in combination with gemcitabine) and who had at least controlled disease with this strategy initial. Overall survival in the intent-to-treat population reached the proposed outcome, with a gain of seven months favoring the experimental arm (21.4 versus 14.3 months). The clinical oncologist at the Curitiba Institute of Hematology and Oncology, a unit of the Oncoclínicas Group, Elge Werneck, explains that this advantage is even more attractive in the PD-L1+ population, in which the statistical benefit was achieved and there was a reduction in the risk of death of 44 %.